A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

I8F-MC-GPIH -

The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Dulaglutide, Tirzepatide
Could I receive a Placebo?
No
Enrollment Goal
282
Trial Dates
Nov 30, 2022 - Aug 12, 2024
How long will I be in the trial?
The study will last approximated 47 weeks and include up to 12 visits.
Trial Phase
IV

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have type 2 diabetes

  • Have stable body weight during the last 90 days

  • Be on a stable dose of dulaglutide (0.75 mg or 1.5 mg) for 6 months

  • Take between 0 to 3 oral diabetes medications

Participants Must Not:

  • Have type 1 diabetes

  • Have a history of pancreatitis

  • Have a history of multiple endocrine neoplasia syndrome type 2 (MEN2) or medullary thyroid cancer (MTC)

  • Have certain diabetic eye diseases

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources

Diabetes Research

To learn more about diabetes and ongoing clinical trials in this area, visit our Diabetes Research page.

Clinical Trial Information

A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.